KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $68.8 million.

  • AbCellera Biologics' Total Current Liabilities fell 13.53% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 13.53%. This contributed to the annual value of $76.6 million for FY2024, which is 35.63% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Total Current Liabilities is $68.8 million, which was up 2.66% from $67.0 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Total Current Liabilities high stood at $221.1 million for Q2 2022, and its period low was $49.5 million during Q3 2021.
  • Its 3-year average for Total Current Liabilities is $89.1 million, with a median of $79.6 million in 2024.
  • As far as peak fluctuations go, AbCellera Biologics' Total Current Liabilities soared by 217.01% in 2022, and later crashed by 58.02% in 2023.
  • Over the past 5 years, AbCellera Biologics' Total Current Liabilities (Quarterly) stood at $120.7 million in 2021, then dropped by 1.95% to $118.3 million in 2022, then increased by 0.59% to $119.0 million in 2023, then tumbled by 35.63% to $76.6 million in 2024, then decreased by 13.53% to $68.8 million in 2025.
  • Its last three reported values are $68.8 million in Q3 2025, $67.0 million for Q2 2025, and $75.4 million during Q1 2025.